Keystone Financial Planning Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 1.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,969 shares of the company’s stock after acquiring an additional 529 shares during the quarter. Johnson & Johnson accounts for 2.6% of Keystone Financial Planning Inc.’s portfolio, making the stock its 20th biggest holding. Keystone Financial Planning Inc.’s holdings in Johnson & Johnson were worth $4,361,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Lenox Wealth Advisors Inc. increased its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at approximately $177,000. Ullmann Financial Group Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $186,000. Finally, Puplava Financial Services Inc. bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at approximately $202,000. 65.61% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently issued reports on JNJ shares. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company an “outperform” rating in a report on Thursday, October 19th. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a report on Wednesday, October 18th. Citigroup Inc. started coverage on Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective for the company. Goldman Sachs Group Inc cut Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their price objective for the company from $125.00 to $130.00 in a report on Wednesday, September 20th. Finally, Jefferies Group LLC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the company from $145.00 to $157.00 in a report on Wednesday, October 11th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and a consensus price target of $143.70.
Shares of Johnson & Johnson (NYSE:JNJ) traded up $0.72 during mid-day trading on Monday, hitting $138.01. The company’s stock had a trading volume of 2,606,800 shares, compared to its average volume of 5,872,014. Johnson & Johnson has a twelve month low of $109.32 and a twelve month high of $144.35. The stock has a market cap of $370,766.63, a PE ratio of 19.33, a price-to-earnings-growth ratio of 2.80 and a beta of 0.82. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same period in the prior year, the business earned $1.68 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. analysts forecast that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.43%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is 58.33%.
WARNING: “Keystone Financial Planning Inc. Grows Holdings in Johnson & Johnson (JNJ)” was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://transcriptdaily.com/2017/11/27/keystone-financial-planning-inc-grows-holdings-in-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.